Non-compete clauses in life sciences employment agreements operate in a fundamentally different context than in most other industries, and the FTC’s 2024 attempt to ban them revealed just how much that context matters. The pharmaceutical and biotechnology sectors are built on proprietary intellectual property — drug candidates, formulation data, clinical trial designs, manufacturing processes, and regulatory strategies — that represents years of investment and constitutes genuine trade secrets under any reasonable legal standard. When a VP of Clinical Development leaves a pharma company for a competitor, the knowledge they carry includes not just general industry expertise but specific information about unpublished clinical data, pipeline prioritization decisions, and FDA interaction strategies that could provide direct competitive advantage.
This piece examines how non-compete clauses uniquely affect pharma and biotech professionals in the wake of the FTC ruling, how garden leave provisions have become the dominant mechanism for managing talent mobility in life sciences, and what the state-by-state landscape looks like across the major life sciences hub states of Massachusetts, New Jersey, California, and North Carolina.
The FTC ruling and its limits
The FTC’s April 2024 final rule purporting to ban most non-compete agreements was immediately challenged in court and blocked by a federal district court in Texas before it could take effect. By late 2025, the rule remained in litigation, and the practical enforceability of non-competes continued to be governed primarily by state law. For life sciences professionals, this means the pre-existing state-by-state framework remains operative, with the FTC ruling having primarily served as a catalyst for companies to voluntarily reexamine their non-compete practices rather than as a binding legal change.
The life sciences industry responded to the FTC ruling differently than most sectors. While technology companies broadly moved toward eliminating non-competes for most employees, pharma and biotech companies largely maintained them for senior scientific, clinical, and commercial leadership. The rationale is defensible: a VP of Regulatory Affairs who has spent 18 months preparing an FDA submission for a novel oncology therapeutic has genuine access to proprietary regulatory strategy, unpublished safety data, and competitive intelligence that would be immediately actionable at a rival company. The trade-secret justification for restricting that individual’s immediate movement to a direct competitor is substantially stronger than the justification for restricting, say, a marketing director at a consumer technology company.
The practical effect of the FTC ruling on life sciences has been a tightening of non-compete scope rather than elimination. Companies that previously applied broad non-competes to all employees above a certain salary threshold have increasingly limited them to individuals with genuine access to proprietary scientific or regulatory information, while relying on non-solicitation and confidentiality agreements for broader employee populations.
Trade secrets and proprietary compounds
The trade-secret dimension of life sciences non-competes is what makes them genuinely different from non-competes in other industries. In pharma and biotech, the information that a senior professional carries includes categories that have no equivalent in most business contexts:
Unpublished clinical data. A Head of Clinical Operations who has seen interim efficacy data from an ongoing Phase 2 trial possesses information that could materially affect a competitor’s development strategy, partnering decisions, or even stock price. This data is protected not only by non-compete clauses but by insider trading regulations, clinical trial confidentiality agreements, and FDA regulations governing the handling of investigational data.
Proprietary formulation and manufacturing data. CMC (Chemistry, Manufacturing, and Controls) professionals carry knowledge about specific drug product formulations, manufacturing process parameters, and analytical methods that are protected as trade secrets and are directly transferable to competitor programs targeting the same mechanism of action. A Director of Process Development who moves from one antibody manufacturer to another brings specific knowledge about cell line development, purification strategies, and scale-up parameters that took years and tens of millions of dollars to develop.
Regulatory strategy intelligence. FDA interactions are confidential between the agency and the sponsor. A VP of Regulatory Affairs who participated in a Type B pre-IND meeting knows exactly what the agency’s concerns were about a specific development program, what endpoints they would accept, and what safety monitoring they would require. That intelligence, applied to a competitor’s program in the same therapeutic area, provides a direct competitive advantage that is difficult to protect through any mechanism other than a temporal restriction on competitive employment.
Garden leave provisions in pharma
Garden leave — a provision requiring the employer to continue paying full salary and benefits during the non-compete period — has become the dominant mechanism for managing senior talent transitions in life sciences. Among our life sciences placements in 2024 and 2025, approximately 65% of VP-and-above offers included garden leave provisions ranging from 6 to 12 months, compared to fewer than 30% in 2019.
The economics of garden leave fundamentally change the non-compete calculus. A pharma company that must pay a VP of Commercial Operations $450,000 in salary plus benefits for 12 months of non-compete enforcement will exercise that option selectively — only when the competitive threat is genuine and the information at risk is truly proprietary. This economic check prevents the overuse of non-competes that characterized the pre-2020 pharma talent market, where companies routinely enforced non-competes against departing executives regardless of whether they posed a genuine competitive threat.
For life sciences professionals negotiating employment agreements, garden leave should be treated as a non-negotiable component of any non-compete clause. The practical argument is straightforward: if the company believes your knowledge is valuable enough to justify restricting your employment for 12 months, it should be valuable enough to compensate you during that restriction. Companies that resist garden leave provisions are effectively asking for free insurance against competitive talent loss, which is an unreasonable position for a senior professional to accept.
State-by-state for LS hub states
The state-by-state variation in non-compete enforceability is particularly consequential for life sciences because the industry is concentrated in a small number of geographic hubs, each with different legal frameworks:
Massachusetts. The Massachusetts Noncompetition Agreement Act (2018) restricts non-competes to 12 months, requires garden leave or equivalent consideration, and prohibits non-competes for employees classified as nonexempt. For the Cambridge/Boston biotech corridor, this means that non-competes are enforceable against senior professionals but only within the 12-month window and only with adequate consideration. The practical effect has been a standardization of 12-month garden leave provisions across the Massachusetts biotech industry.
New Jersey. New Jersey does not have a specific non-compete statute but enforces non-competes under common law, applying a reasonableness standard that considers geographic scope, duration, and the employer’s legitimate business interests. For the New Jersey pharma corridor (the concentration of major pharma headquarters along the I-95/Route 1 corridors), courts have historically been willing to enforce 12- to 18-month non-competes for senior scientific and commercial leadership, particularly when trade-secret exposure is documented.
California. California’s blanket prohibition on non-competes (Business and Professions Code Section 16600) applies without exception to life sciences employees, including those with access to highly proprietary drug development data. This creates a structural advantage for San Francisco and San Diego biotech clusters in talent recruitment: candidates moving to California-based companies are freed from non-competes they signed in other states, regardless of the governing-law provision in their employment agreements. California courts have repeatedly refused to enforce out-of-state non-competes against California residents.
North Carolina. North Carolina’s Research Triangle region has become an increasingly significant biotech and pharma hub, and its non-compete law provides relatively strong employer protections compared to Massachusetts or California. Non-competes are enforceable if reasonable in scope, geography, and duration, with courts generally accepting 12- to 24-month restrictions for professionals with genuine trade-secret exposure. The absence of a garden leave requirement makes North Carolina non-competes potentially more restrictive for departing professionals.
Negotiating non-competes in life sciences
For senior life sciences professionals managing non-competes in employment negotiations, several strategies are particularly effective given the industry’s unique intellectual property landscape:
Narrow by therapeutic area rather than by industry. A blanket non-compete prohibiting employment at "any pharmaceutical or biotechnology company" is almost certainly broader than necessary and may not survive judicial scrutiny. Propose narrowing the restriction to companies with active programs in the same therapeutic area and mechanism of action as the programs you worked on. A CMO who oversaw an anti-CD20 antibody program in oncology has limited competitive overlap with a company developing a GLP-1 agonist for metabolic disease, and the non-compete should reflect that distinction.
Define proprietary information specifically. Rather than accepting a vague definition of confidential information, propose an enumerated list of the specific categories of information that justify the non-compete: specific compound identifiers, unpublished clinical data, FDA correspondence, proprietary manufacturing processes. This specificity makes the non-compete more enforceable (courts favor specific definitions) while also making it more navigable for the departing professional, who can clearly identify which activities are restricted and which are not.
Insist on garden leave with full benefits continuation. In life sciences, where the non-compete justification is strongest, the garden leave provision should include not just base salary but target bonus, benefits continuation, and continued equity vesting. The argument is that the non-compete period represents enforced idleness in service of the employer’s competitive interests, and the professional should be made whole for that period.
Final thoughts
Non-compete clauses in life sciences occupy a unique position in employment law because the trade-secret justification for restricting talent mobility is genuinely stronger in pharma and biotech than in most other industries. The FTC’s attempted ban did not change this reality; if anything, it clarified the distinction between industries where non-competes are primarily about restricting labor mobility (which the FTC targeted) and industries where they serve a legitimate trade-secret protection function (which courts have consistently upheld).
For life sciences professionals, the practical guidance is to negotiate non-competes as seriously as you negotiate compensation, with particular attention to scope narrowing, garden leave provisions, and the state-law framework that governs your specific situation. For related context on how compensation and career progression work at the senior level in pharma and biotech, see our Director-to-VP career analysis and our biotech equity negotiation guide.